Merck & Company (MRK): Price Target and June Short Interest Disclosure

Merck & Company (MRK) : The highest level Merck & Company (MRK) is projected to reach is $80 for the short term and the lowest estimate is at $50. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $62.58 and the possibility the share price can swing is $8.47.

Merck & Company (MRK) stated loss of 665,630 shares or 2.1% in the short interest. The short interest registered from 30,994,348 on June 15,2016 to 30,328,718 on June 30,2016. In terms of floated shares, the shorted positions stood at 1.1%. The stock has been averaging 12,407,169 shares daily in trading and would need 2 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, Equity Analysts at the Brokerage Firm, Jefferies, maintains their rating on the shares of Merck & Company (NYSE:MRK). Jefferies has a Hold rating on the shares. As per the latest research report, the brokerage house lowers the price target to $53 per share from a prior target of $54. The rating by the firm was issued on June 14, 2016.


Merck & Company (NYSE:MRK): stock turned positive on Thursday. Though the stock opened at $59.87, the bulls momentum made the stock top out at $59.93 level for the day. The stock recorded a low of $59.48 and closed the trading day at $59.65, in the green by 0.17%. The total traded volume for the day was 7,345,481. The stock had closed at $59.55 in the previous days trading.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.